Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with, or are suspected of having, a melanocytic lesion (a type of skin growth involving pigment-producing cells), including types such as conventional melanoma, Spitzoid melanoma or atypical Spitz tumor, congenital melanoma, melanoma arising from a large birthmark, or pigment-related lesions whose behaviour is uncertain
- People who were younger than 19 years old at the time of their diagnosis
- People for whom tissue samples are available for biological research
- People who are already enrolled, or will be enrolled, in a related tissue banking study called the TBANK protocol at St. Jude Children's Research Hospital before any research tests are carried out on their biological samples
Who may not be able to join:
- People whose melanoma originated in the eye (ocular melanoma)
- People, or their legal guardian, who are unable or unwilling to give consent to participate
- People whose tissue diagnosis is something other than the specific melanocytic lesion types listed above
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Alberto Pappo, MD, St. Jude Children's Research Hospital
Phone: 866-278-5835
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Genomic profile
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.